SS
TVRD

Steve Schonfeld’s Tvardi Therapeutics TVRD Stock Holding History

Steve Schonfeld’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,132
Closed -$746K – 2737
2025
Q3 		$746K Buy
+19,132
New +$545K ﹤0.01% 1518
2020
Q3 		– Sell
-527
Closed -$324K – 1725
2020
Q2 		$324K Buy
+527
New +$291K 0.01% 965
2016
Q2 		– Sell
-278
Closed -$62K – 546
2016
Q1 		$62K Buy
+278
New +$83K 0.03% 294

Other funds holding TVRD

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Steve Schonfeld's TVRD Position: Q4 2025 in Review

Steve Schonfeld sold out of Tvardi Therapeutics (TVRD) in Q4 2025, closing a stake of 19,132 shares — an estimated $746K sold.

Steve Schonfeld first reported a position in TVRD in Q1 2016 and held it in 3 quarters. The position peaked at $746K in Q3 2025. 67 funds tracked by Wall St. Rank hold TVRD as of Q4 2025.

  • Steve Schonfeld reported no remaining Tvardi Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Steve Schonfeld sold 19,132 Tvardi Therapeutics shares in Q4 2025, an estimated $746K.
  • Steve Schonfeld first reported a position in Tvardi Therapeutics in Q1 2016 and held it in 3 quarters.
  • Steve Schonfeld's Tvardi Therapeutics position peaked at $746K in Q3 2025.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.